Re-evaluation Note REV2024-01

Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2024-2029

(publié aussi en français)

3 May 2024

This document is published by the Health Canada Pest Management Regulatory Agency. For further information, please contact:

Publications
Pest Management Regulatory Agency
Health Canada
2 Constellation Drive
8th floor, A.L. 2608 A
Ottawa, Ontario K1A 0K9

Internet: canada.ca/pesticides
pmra.publications-arla@hc-sc.gc.ca

Information Service:
1-800-267-6315
pmra.info-arla@hc-sc.gc.ca

Canada

ISSN: 1925-0630 (print)
1925-0649 (online)

Catalogue number: H113-5/2024-1E (print version)
H113-5/2024-1E-PDF (PDF version)

Table of Contents

Background

The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work (in other words, the post-market reviews) planned by Health Canada's Pest Management Regulatory Agency (PMRA) for the next five fiscal years from 1 April 2024 to 31 March 2029.

This work plan includes the target dates for the proposed and final decisions to be published since 1 April 2024, the status of all open re-evaluations and special reviews, as well as new re-evaluations expected to be initiated from 1 April 2024 to 31 March 2029. This document presents updates to the information last published in Re-evaluation Note REV2023-01, *Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2023-2028*.

Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide product may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the *Pest Control Products Act*. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.

As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, *Management of Pesticides Re-evaluation Policy*. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluations in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, *Approach to Special Reviews of Pesticides.*

As required under the *Pest Control Products Act*, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations and decisions for pesticides by visiting the Pesticides and pest management section of Canada.ca.

This five-year work plan may change in response to workload and emerging issues that require priority action. While this work plan will be updated annually, during the course of the year, interested stakeholders can monitor the PMRA's Public Registry to view the announcement of new re-evaluations and special reviews, as well as other documents relevant to specific post-market reviews.

Part A – Current re-evaluation and special review work plan (Tables 1–3)

The post-market review program workload remains significant. In recent years, Health Canada focused its resources on the completion of the remaining older pesticide active ingredients registered before 1995, and completed their re-evaluation by 31 March 2023. Health Canada introduced the risk based prioritization for the re-evaluation program in 2019 (REV2020-01), and ongoing efforts to streamline the re-evaluation processes for lower priority actives resulted in the removal of the backlog of lower priority actives. The re-evaluation reviews of several higher priority actives have been delayed due to the demands of focusing resources on completing the re-evaluations of older pesticides, and other priorities including responding to litigations, as well as notices of objection, and the scientific complexity associated with certain pesticide reviews. The number of re-evaluation initiations currently required as per the 15-year legislative requirement continues to be high and given the current resource capacity considerations, the backlog is growing.

As part of its Transformation Agenda (PMRA Transformation), the PMRA is building upon existing risk prioritization efforts to develop a proportional effort approach that prioritizes workload across the full pesticide program. Implementation of proportional effort will enable the PMRA to better focus review efforts to increase overall protection and make progress to eliminate the re-evaluation backlog. The proportional effort policy is expected to be issued for public consultation in mid-summer 2024. Future work plans will reflect any new prioritization or timelines, once the proportional effort policy is finalized.

In addition to proportional effort, the PMRA has recently consulted on the continuous oversight lifecycle approach (Proposed Continuous Oversight Policy) that enhances our ability to keep pace with new science information and takes necessary action where needed to protect human health and the environment. A final continuous oversight approach taking into consideration the comments received during consultation is expected to be issued in late Spring 2024. Continuous oversight reduces reliance on the re-evaluation program by identifying and addressing risks sooner thereby decreasing the complexity of re-evaluation reviews.

During the post-market reviews, when necessary, Health Canada will seek independent scientific advice through Science Advisory Committee to better inform its evidence-based decisions.

Part A, Table 1 Targets for consultation and final decisions of special reviews

Active ingredient name	Target date of consultation[1]
Chlorpropham	Q3 (2025–26)
Desmedipham	Q4 (2027–28)
Dicamba - Dicamba (present as acid, ester, salts) - Dicamba (present as n,n-bis(3-aminopropyl)methylamine salt) - Dicamba (present as monoethanolamine salt)	January 2025

Active ingredient name	**Target date of consultation[1]**
- Dicamba (present as n-(2-aminoethyl)-1,2-ethanediamine salt) - Dicamba (present as acid) - Dicamba (present as potassium salt) - Dicamba (present as sodium salt) - Dicamba (present as dimethylamine salt) - Dicamba (present as diglycolamine salt) - Dicamba (present as isopropylamine salt) - Dicamba (present as diethanolamine salt)	
Ethofumesate	Q4 (2026–27)
Glufosinate ammonium	Q1 (2026–27)
Hydantoins - Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins - Available bromine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins - Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, 1,3-dichloro-5-ethyl-5-methylhydantoin and related hydantoins - Available Chlorine Present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3- Dichloro-5-Ethyl-5-Methylhydantoin	Q3 (2025–26)
Iodocarb (3-iodo-2-propynyl butyl carbamate)	October 2024
MCPA - MCPA (present as acid) - MCPA (present as amine salts: diethanolamine, dimethylamine, or mixed amines) - MCPA (present as esters) - MCPA (present as potassium salt or as sodium salt)	Q3 (2025–26)
Novaluron	Q1 (2025-26)
Propiconazole	Q1 (2026–27)
Pydiflumetofen	November 2024
Thiacloprid	Q4 (2026–27)
Active ingredient name	**Target date of final decision[1]**
Atrazine	Q2 (2025–26)
Chlorothalonil	March 2025
Fosetyl aluminum	August 2024
Methyl bromide	Consultation started 28 March 2024

1 Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Part A, Table 2a Targets for consultation and final re-evaluation decisions

Active ingredient name	Re-evaluation category	Target date[1]
Proposed re-evaluation decisions		**Target date of consultation**
6-Benzylaminopurine	1	Q2 (2026–27)
3-Methyl-2-Cyclohexen-1-one	3	September 2024
Acetamiprid	1	Q2 (2026–27)
Bensulide	1	Q1 (2027–28)
Carbon dioxide cluster: - Carbon dioxide gas - Liquid carbon dioxide	2	October 2024
Cellulose	3	January 2025
Clothianidin general re-evaluation[2]	1	Q2 (2025–26)
Cyprodinil	1	Q4 (2025–26)
D-cis, trans-allethrin	1	Q2 (2026–27)
DEET plus related active toluamides	1	Q1 (2025–26)
Famoxadone	1	February 2025
Fatty Acid cluster: - Potassium Salts of Fatty Acids - Triethanolamine Salts of Fatty Acids - Fatty Acids - Ammonium Salt of Fatty Acid	2	January 2025
Fenamidone	1	Q1 (2025–26)
Ferric Sodium Ethylenediaminetetraacetic Acid	3	Q1 (2025–26)
Fluazinam	1	Q4 (2025–26)
German Cockroach Extract	3	March 2025
Gibberellins cluster: - Gibberellic acid - Gibberellins A4A7	3	Q1 (2025–26)
Glufosinate ammonium	1	Q1 (2026–27)
Mecoprop cluster: - Mecoprop-P (present as Acid) - Mecoprop-P (present as Dimethylamine Salt) - Mecoprop-P (present as Potassium Salt)	1	Q3 (2025–26)
Methoxyfenozide	1	Q4 (2026–27)
Naled	1	Q3 (2026–27)
Nonylphenoxypolyethoxyethanol	3	March 2025
Phorate	1	Q3 (2026–27)
Picolinafen	1	Q3 (2027–28)
Potassium bicarbonate	2	February 2025

Active ingredient name	Re-evaluation category	Target date[1]
Rodenticide Cluster: - Brodifacoum - Bromadiolone - Bromethalin - Chlorophacinone - Diphacinone (present in free form or as sodium salt) - Warfarin (present in free form or as sodium salt) - Zinc phosphide - Difethialone	1	Q2 (2026–27)
Spinetoram	1	Q2 (2025–26)
Spinosad	1	Q2 (2025–26)
Streptomyces lydicus strain WYEC108	3	December 2024
Sulphur	2	March 2025
Tetrachlorvinphos	1	Q2 (2027–28)
Thiacloprid	1	Q4 (2026–27)
Thiamethoxam general re-evaluation[2]	1	Q2 (2025–26)
Cumulative Health Risk Assessment: N-Methyl Carbamates	1	Q4 (2025–26)
Cumulative Health Risk Assessment: Organophosphates[3] (project plan)	1	October 2024
Final re-evaluation decisions		**Target date of final decision**
Abamectin	1	Q1 (2025–26)
Agrobacterium radiobacter strain K84 and K1026	3	June 2024
Azoxystrobin	1	Q2 (2026–27)
Flufenacet	1	August 2024
Foramsulfuron	3	Consultation started 28 March 2024
Methyl bromide	1	Consultation started 28 March 2024
Natamycin	3	Consultation started 6 March 2024
Octenol	3	June 2024
Silicon dioxide cluster: - Silica aerogel - Silicon dioxide	3	August 2024
Sodium chloride	3	May 2024
S-metolachlor and R-enantiomer	1	Consultation started 29 February 2024
Tebuconazole	1	September 2024

1 Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

2 Cyclical re-evaluations of clothianidin and thiamethoxam were initiated in 2016 to assess their value, as well as human health and environmental risks other than impacts on pollinators and aquatic invertebrates. The assessment of the impacts on pollinators was completed in 2019. Special reviews of clothianidin and thiamethoxam related to aquatic invertebrates were completed in March 2021. Special reviews of clothianidin, thiamethoxam and imidacloprid related to squash bees were completed in February 2022.

3 A separate project plan will be published as per process described in Science Policy Note SPN2018-02, *Cumulative Health Risk Assessment Framework*.

Part A, Table 2b Status of other active ingredients (currently in early stage of re-evaluation process)

The re-evaluations of the following active ingredients are in the early stage of the re-evaluation process, and Health Canada will provide an updated status in the next work plan to be published in spring 2025:

Active ingredient name	Current status
1,2-Dibromo-2,4-Dicyanobutane	Scoping phase completed
2-(Hydroxymethyl)-2-nitro-1,3-propanediol	Scoping phase completed
2-(Thiocyanomethylthio)benzothiazole	Scoping phase
10,10'-Oxybis (Phenoxarsine)	Scoping phase completed
Acifluorfen, present as sodium salt	Scoping phase
Dioxaborinanes cluster: - 2,2-(1-Methyltrimethylenedioxy)bis-(4-methyl1,3,2-dioxaborinane) - 2,2-Oxybis(4,4,6-trimethyl-1,3,2-dioxaborinane)	Scoping phase
Acequinocyl	Scoping phase
Aminopyralid - Aminopyralid - Aminopyralid triisopropanolamine salt - Aminopyralid potassium salt	Scoping phase
Ammonium Bromide	Scoping phase
Antimicrobials cluster: - 2,2-Dibromo-3-nitrilopropionamide - 2-Methyl-4-isothiazolin-3-one - 5-Chloro-2-methyl-4-isothiazolin-3-one - 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone - Bronopol - Methylene bis(thiocyanate)	Scoping phase
Atrazine (plus related active Triazines)	Scoping phase
Triazinetrione cluster: - Available Chlorine, present as Sodium Dichloro-S-Triazinetrione - Available Chlorine, present as Trichloro-S-Triazinetrione - Trichloro-S-Triazinetrione	Scoping phase
Bentazon cluster: - Bentazon (present as Sodium Salt) - Bentazone	Scoping phase
Bifenazate	Scoping phase completed
Bispyribac-Sodium (KIH-2023)	Scoping phase
Boscalid	Scoping phase completed
Bromacil (present in free form, as dimethylamine salt, or as lithium salt)	Scoping phase
Carbendazim	Scoping phase
Carfentrazone-ethyl	Scoping phase

Active ingredient name	Current status
Chlorpropham	Scoping phase
Clomazone	Scoping phase
Cyazofamid	Scoping phase
Daminozide	Scoping phase completed
Dichlobenil	Scoping phase
Didecyldimethylammonium (present as Carbonate and Bicarbonate Salts)	Scoping phase
Diflubenzuron	Scoping phase
Diphenylamine	Scoping phase
Diuron	Scoping phase
Endothal cluster: - Endothal - Endothal, present as N,N-dimethylalkylamine salt	Scoping phase
EPTC (S-ethyl N,N-dipropylcarbamothioate)	Scoping phase
Etridiazole	Scoping phase
Fenbutatin Oxide	Scoping phase
Fish toxicants cluster: - 4-Nitro-3-(trifluoromethyl) phenol sodium salt - Niclosamide	Scoping phase completed
Fluvalinate-tau	Scoping phase
Iodosulfuron-methyl-sodium	Scoping phase completed
Ipconazole	Scoping phase completed
Mesotrione	Scoping phase completed
Metalaxyl cluster: - Metalaxyl - Metalaxyl-M and S-Isomer	Scoping phase
Metribuzin	Scoping phase
Napropamide	Scoping phase
Novaluron	Scoping phase
Oxamyl	Scoping phase
Oxyfluorfen	Scoping phase
Pinoxaden	Scoping phase
Prohexadione calcium	Scoping phase
Prometryne Plus Related Active Triazines	Scoping phase
Prothioconazole	Scoping phase
Pyrimethanil	Scoping phase
Pyraclostrobin	Scoping phase completed
Pyrasulfotole	Scoping phase
Pyroxsulam	Scoping phase
Rotenone	Scoping phase
Sethoxydim	Scoping phase
(S)-Methoprene	Scoping phase
Spirodiclofen	Scoping phase
Spiromesifen	Scoping phase

Active ingredient name	Current status
Sulfonyl Ureas cluster: - Chlorsulfuron - Ethametsulfuron-Methyl - Metsulfuron-Methyl - Nicosulfuron - Rimsulfuron - Thifensulfuron-Methyl	Scoping phase
Sulfuryl fluoride	Scoping phase
Terbacil	Scoping phase
Topramezone	Scoping phase
Triallate	Scoping phase
Triclopyr (present as butoxyethyl ester)	Scoping phase
Trifloxystrobin	Scoping phase completed

Part A, Table 3 Re-evaluation Initiations between 1 April 2024 and 31 March 2025

For the re-evaluation initiations between 1 April 2024 to 31 March 2025, risk-based prioritization of actives as higher or lower priority based on the risk prioritization approach implemented since 2019 (REV2020-01) was not conducted. As part of the PMRA's transformation initiative, a proportional effort policy is expected to be issued for consultation in mid-summer 2024, and prioritisation of re-evaluations initiated from 1 April 2024 onwards will be part of this proportional effort approach.

To further improve transparency for stakeholders and registrants, specific month of initiation of re-evaluation is included.

Active ingredient	Initiation dates
1,2-Benzisothiazolin-3-one	To be initiated July 2024
2,4-D cluster: - 2,4-D (present as Acid) - 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts) - 2,4-D (present as choline salt) - 2,4-D (present as Low Volatile Esters)	To be initiated May 2024
2-Phenylphenol and Salts cluster: - 2-Phenylphenol - 2-Phenylphenol (present as Potassium Salt) - 2-Phenylphenol (present as Sodium Salt)	To be initiated April 2024

Active ingredient	Initiation dates
Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC): - N-Alkyl (25% C12, 60% C14, 15% C16) Dimethyl Benzyl Ammonium Chloride - N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride - N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride - N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride - N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride - Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride - N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate - N-Dialkyl (5% C12, 60% C14, 30% C16, 5% C18) Methyl Benzyl Ammonium Chloride	To be initiated March 2025
Bacillus thuringiensis cluster: - *Bacillus thuringiensis* Berliner ssp. *kurstaki* Strain HD-1 - *Bacillus thuringiensis* Serotype H-14 - *Bacillus thuringiensis* ssp. *tenebrionis*	To be initiated May 2024
Beauveria bassiana Strain HF23	To be initiated April 2024
Bromoxynil	To be initiated May 2024
Chlorantraniliprole	To be initiated May 2024
Chlorthal (present as Dimethyl Ester)	To be initiated August 2024
Clonostachys rosea strain J1446	To be initiated April 2024
Cloransulam-Methyl	To be initiated September 2024
Coniothyrium minitans Strain CON/M/91-08	To be initiated March 2025
Cyprosulfamide	To be initiated November 2024

Active ingredient	Initiation dates
Dicamba cluster: - Dicamba (present as Acid) - Dicamba (present as Acid, Ester, Salts) - Dicamba (present as Diethanolamine Salt) - Dicamba (present as Diglycoamine Salt) - Dicamba (present as Dimethylamine Salt) - Dicamba (present as Isopropylamine Salt) - Dicamba (present as Monoethanolamine Salt) - Dicamba (present as N-(2-Aminoethyl)-1,2-Ethanediamine Salt) - Dicamba (present as N,N-Bis(3-Aminopropyl)Methylamine Salt) - Dicamba (present as Potassium Salt) - Dicamba (present as Sodium Salt)	To be initiated August 2024
Didecyl Dimethyl Ammonium Chloride Cluster (DDAC): - Didecyl Dimethyl Ammonium Chloride – Other - Didecyldimethylammonium (present as carbonate and icarbonate Salts) - Dioctyl Dimethyl Ammonium Chloride (present as Carbonate and Bicarbonate Salts) - Octyl Decyl Dimethyl Ammonium Chloride - Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)	To be initiated March 2025
Dodine	To be initiated May 2024
Ethofumesate	To be initiated April 2024
Flumioxazin	To be initiated March 2025
Glutaraldehyde	To be initiated January 2025
Imazapyr	To be initiated April 2024
Maleic Hydrazide	To be initiated January 2025
Mandipropamid	To be initiated August 2024
MCPA cluster: - MCPA (present as Acid) - MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines) - MCPA (present as Esters) - MCPA (present as Potassium Salt or as Sodium Salt)	To be initiated May 2024
Metaldehyde	To be initiated November 2024
Metarhizium brunneum Strain F52	To be initiated February 2025
Mineral Oil	To be initiated August 2024
Phosphonic acid cluster: - Mono- and Di-Potassium Salt of Phosphorous Acid - Mono- and Di-basic Sodium, Potassium, and Ammonium Phosphites	To be initiated September 2024

Active ingredient	Initiation dates
Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt)	To be initiated February 2025
Oxirane Derivatives - 50% Minimum	To be initiated April 2024
Ozone	To be initiated November 2024
Pendimethalin	To be initiated June 2024
Picloram cluster: - Picloram (present as Potassium Salt) - Picloram (present as Acid) - Picloram (present as Amine Salts)	To be initiated January 2025
Propylene Glycol	To be initiated August 2024
Pyrazon	To be initiated April 2024
Industrial Uses of Sodium Chlorite and Sodium Chlorate cluster: - Sodium Chlorite - Sodium Chlorate	To be initiated April 2024
Spirotetramat	To be initiated June 2024
Streptomycin	To be initiated July 2024
Sulfentrazone	To be initiated May 2024
Tetrakis hydroxymethyl phosphonium sulphate	To be initiated May 2024
Thiencarbazone-Methyl	To be initiated November 2024
Triazole Cumulative Risk Assessment	To be initiated October 2024

Part B – Re-evaluation initiations anticipated between April 2025 and March 2029

The initiation date of the re-evaluation of a particular active ingredient is based on the date of its initial registration, or the date of the last completed re-evaluation.

Part B, Table 1 Re-evaluation Initiations between 1 April 2025 and 31 March 2026

The month in which the re-evaluation for the active ingredients to be initiated between 1 April 2025 to 31 March 2026 is also provided to further improve transparency for registrants and stakeholders.

Active Ingredient	Initiation dates
Beauveria bassiana Strain GHA	To be initiated June 2025
Bifenthrin	To be initiated February 2026
Carbathiin	To be initiated June 2025
Chlormequat Chloride	To be initiated March 2026
Desmedipham	To be initiated October 2025
Diazinon	To be initiated November 2025
Dimethenamid-P	To be initiated April 2025
Dithiopyr	To be initiated September 2025
Formetanate Hydrochloride	To be initiated April 2025
Hexazinone	To be initiated April 2025

Active Ingredient	Initiation dates
Imazamethabenz-Methyl	To be initiated April 2025
Lime Sulphur Or Calcium Polysulphide	To be initiated May 2025
N-Coco-Alkyltrimethylene Diamines present as: - Monobenzoate Salt - Alkyl-1,3-Propylene Diamine Acetates - 1-Alkylamino-3-Aminopropane (Alkyl Groups As Derived From Coconut Oil Fatty Acids)	To be initiated December 2025
N-Decanol N-Octanol	To be initiated September 2025
Nosema (Paranosema) locustae Canning	To be initiated April 2025
Oxycarboxin	To be initiated June 2025
Phenmedipham	To be initiated September 2025
Propyzamide	To be initiated September 2025
Pseudomonas fluorescens A506	To be initiated July 2025
Tribenuron-Methyl	To be initiated June 2025
Trifluralin	To be initiated September 2025
R-(-)-1-Octen-3-Ol	To be initiated December 2025
Saflufenacil	To be initiated February 2026
Simazine Plus Related Active Triazines	To be initiated March 2026
Verticillium albo-atrum, Isolate Wcs850	To be initiated October 2025

Part B, Table 2 Future re-evaluation initiations between 1 April 2026 and 31 March 2029

1 April 2026 to 31 March 2027
Diquat
Iron (present as FeHEDTA)
Tembotrione
Naphthalene
Animal repellent cluster: - Castor Oil - Dried Eggs - Fish Meal Mixture - Fish Oil Mixture - Garlic Oil - Meat Meal Mixture - Wintergreen Oil
Pseudomonas syringae - Strain ESC-10
Lactobacillus casei Strain LPT-111
Lactococcus lactis ssp. lactis Strain Ll64/CSL
Lactococcus lactis ssp. lactis Strain Ll102/CSL
Lactic Acid
Citric Acid
Mesosulfuron-Methyl
Metrafenone
Butoxypolypropylene Glycol
Paradichlorobenzene

Tefluthrin
Flonicamid
Acibenzolar-S-Methyl
Iodocarb (3-iodo-2-propynyl butyl carbamate)
Tralkoxydim
Thiabendazole
1,4-Dimethylnaphthalene
Diclorprop cluster: - Dichlorprop-P - Dichlorprop-P (present as Dimethylamine Salt) - Dichlorprop P-Isomer (present as 2-Ethylhexyl Ester)
Thymol
Lactobacillus rhamnosus Strain LPT-21
Lactococcus lactis ssp. cremoris Strain M11/CSL
Imazethapyr
Sodium Fluoride
Trimethoxysilyl quats cluster: - 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trimethoxysilsyl quats) - 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trihydroxysilyl quats)
Diodofon
Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine
Oxalic Acid Dihydrate
D-Limonene
Saponins Of Chenopodium Quinoa
1 April 2027 to 31 March 2028
Arsenic Acid
Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin
Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
Bacillus firmus I-1582
Chromic Acid
Clopyralid
Copper (present as Basic Copper Carbonate)
Copper (present as Copper 8-Quinolinolate)
Copper (present as Copper Naphthenate)
Creosote
Cydia pomonella granulovirus (Strain M)
Extract of *Reynoutria sachalinensis*
Fluopicolide
Formaldehyde
Icaridin
Indaziflam
Metofluthrin
Oriental Mustard Seed Meal
Paecilomyces fumosoroseus Strain FE 9901

Paraformaldehyde
Penflufen
Penthiopyrad
Phoma Macrostoma
Propiconazole
Trichoderma asperellum Strain T34
Zinc (present as Zinc Oxide)
Zinc as Elemental (present as Zinc Naphthenate)
1 April 2028 to 31 March 2029
Ametoctradin
Ammonia (present as Ammonium Sulfate)
Aureobasidium pullulans cluster: - *Aureobasidium pullulans* Strain DSM 14940 and DSM 14941 - *Aureobasidium pullulans* Strain DSM 14940 - *Aureobasidium pullulans* Strain DSM 14941
Bacillus subtilis var. amyloliquefaciens Strain FZB24
Clavibacter michiganesis spp. michiganensis Bacteriophage
Cloquintocet-Mexyl
Denatonium Benzoate
Ethalfluralin
Fenoxaprop-P-Ethyl
Fluazifop-P-Butyl and S-Isomer
Fluopyram
Fluoxastrobin
Fluxapyroxad
Kasugamycin (Present as Hydrochloride Hydrate)
Malathion
MCPB cluster: - MCPB - MCPB (present as Sodium Salt)
Mint oil cluster: - Cornmint Oil - Methyl Salicylate
Octadecadien-1-ol cluster: - (E,Z)-2,13-Octadecadien-1-yl Acetate - (Z,Z)-3,13-Octadecadien-1-ol - (E,Z)-3,13-Octadecadien-1-ol
Picoxystrobin
Poly[Oxyethylene(Dimethyliminio)Ethylene (Dimethyliminio)Ethylene Dichloride]
Potassium Dimethyldithiocarbamate Salts
Pseudomonas fluorescens Strain CL145A
Pyroxasulfone
Sedaxane
Sulfoxaflor
Tetraconazole
Trichoderma virens Strain G-41